John Akudugu1, Antonio Serafin, Lothar Böhm. 1. Division of Radiobiology, Department of Medical Imaging and Clinical Oncology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, 7505, South Africa, jakudugu@sun.ac.za.
Abstract
PURPOSE: To assay for uPA and PAI-1 in prostate tissue from 40 patients with prostatic disease and to examine the robustness of the correlation of the uPA/PAI-1 ratio with benign prostatic hyperplasia (BPH) and prostate cancer (PCa), previously identified in a different cohort of 62 patients. METHODS: uPA and PAI-1 were extracted from liquid N2 frozen homogenised prostate tissue with TRIS/Triton pH 8.5 buffer and measured by ELISA (FEMTELLE). RESULTS: The concentration of uPA (mean ± SD) was found to be 0.1177 ± 0.0266 (range 0.0070-0.7200; n = 30) and 0.1092 ± 0.0130 (range 0.0040-0.7800; n = 70) for PCa and BPH patients, respectively. The concentration of PAI-1 was found to be 5.236 ± 0.688 ng/mg protein (range 1.10-15.19; n = 30) and 4.975 ± 0.501 ng/mg protein (range 0.20-25.00; n = 70) for PCa and BPH patients, respectively. The mean uPA/PAI-1 ratio was found to be 0.0479 ± 0.0060 (range 0.0043-0.1200; n = 30) in PCa samples and was significantly higher than BPH samples where the ratio was 0.0332 ± 0.0023 (range 0.0040-0.0860; n = 70) (P = 0.0064). In PCa patients older than 68 years, the uPA/PAI-1 ratio was above 0.050 reaching 0.100 in 73-year-old patients. CONCLUSIONS: Evaluation of 100 patients with prostatic pathologies (70 PCa; 30 BPH) shows the uPA/PAI-1 ratios in PCa patients to be significantly higher than in BPH patients. This is fully consistent with a previous study on 62 patients (16 were PCa; 46 BPH) where the ratios were 0.055 and 0.031 for PCa and BPH patients, respectively (P = 0.0028). In older PCa patients, uPA/PAI-1 ratios tend to be higher.
PURPOSE: To assay for uPA and PAI-1 in prostate tissue from 40 patients with prostatic disease and to examine the robustness of the correlation of the uPA/PAI-1 ratio with benign prostatic hyperplasia (BPH) and prostate cancer (PCa), previously identified in a different cohort of 62 patients. METHODS:uPA and PAI-1 were extracted from liquid N2 frozen homogenised prostate tissue with TRIS/Triton pH 8.5 buffer and measured by ELISA (FEMTELLE). RESULTS: The concentration of uPA (mean ± SD) was found to be 0.1177 ± 0.0266 (range 0.0070-0.7200; n = 30) and 0.1092 ± 0.0130 (range 0.0040-0.7800; n = 70) for PCa and BPH patients, respectively. The concentration of PAI-1 was found to be 5.236 ± 0.688 ng/mg protein (range 1.10-15.19; n = 30) and 4.975 ± 0.501 ng/mg protein (range 0.20-25.00; n = 70) for PCa and BPH patients, respectively. The mean uPA/PAI-1 ratio was found to be 0.0479 ± 0.0060 (range 0.0043-0.1200; n = 30) in PCa samples and was significantly higher than BPH samples where the ratio was 0.0332 ± 0.0023 (range 0.0040-0.0860; n = 70) (P = 0.0064). In PCa patients older than 68 years, the uPA/PAI-1 ratio was above 0.050 reaching 0.100 in 73-year-old patients. CONCLUSIONS: Evaluation of 100 patients with prostatic pathologies (70 PCa; 30 BPH) shows the uPA/PAI-1 ratios in PCa patients to be significantly higher than in BPH patients. This is fully consistent with a previous study on 62 patients (16 were PCa; 46 BPH) where the ratios were 0.055 and 0.031 for PCa and BPH patients, respectively (P = 0.0028). In older PCa patients, uPA/PAI-1 ratios tend to be higher.
Authors: Shahrokh F Shariat; Claus G Roehrborn; John D McConnell; Sangtae Park; Nina Alam; Thomas M Wheeler; Kevin M Slawin Journal: J Clin Oncol Date: 2007-02-01 Impact factor: 44.544
Authors: N Harbeck; M Schmitt; C Meisner; C Friedel; M Untch; M Schmidt; C G J Sweep; B W Lisboa; M P Lux; T Beck; S Hasmüller; M Kiechle; F Jänicke; C Thomssen Journal: Eur J Cancer Date: 2013-03-13 Impact factor: 9.162
Authors: Amit Gupta; Yair Lotan; Raheela Ashfaq; Claus G Roehrborn; Ganesh V Raj; Corinne C Aragaki; Francesco Montorsi; Shahrokh F Shariat Journal: Eur Urol Date: 2008-06-23 Impact factor: 20.096
Authors: Lothar Böhm; Antonio Serafin; John Akudugu; Pedro Fernandez; Andre van der Merwe; Naseem A Aziz Journal: J Cancer Res Clin Oncol Date: 2013-04-18 Impact factor: 4.553
Authors: Joanne Louise Welton; Paul Brennan; Mark Gurney; Jason Paul Webber; Lisa Kate Spary; David Gil Carton; Juan Manuel Falcón-Pérez; Sean Peter Walton; Malcolm David Mason; Zsuzsanna Tabi; Aled Clayton Journal: J Extracell Vesicles Date: 2016-06-29
Authors: Xiuju Li; Benjamin Buckley; Konstantin Stoletov; Yang Jing; Marie Ranson; John D Lewis; Mike Kelso; Larry Fliegel Journal: Int J Mol Sci Date: 2021-12-09 Impact factor: 5.923